Search the Newsreel

Prediction: AbbVie Will End The Year at This Price

24/7 Wall St. predicts AbbVie (ABBV) will end the year with a "buy" rating and a price target of $297.71, representing a 20.92% upside from its current price. This optimistic outlook is driven by the strong performance of drugs like Skyrizi and Rinvoq, which …

Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's …

DBV Technologies stock rebounds 2.5% with RSI in oversold territory at 29

DBV Technologies stock gained 2.42% to €2.37, ranking among the strongest gains of the SBF 120, despite being down nearly 18% over one month and more than 29% over three months. The stock's rebound from its €2.31 support level and an RSI of 29 …

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Central Pacific Bank Trust Division Sells 4,628 Shares of AbbVie Inc. $ABBV

Central Pacific Bank Trust Division significantly reduced its stake in AbbVie Inc. by 44.5% in the second quarter, selling 4,628 shares and retaining 5,766 shares valued at $1.45 million. Despite this sale, AbbVie reported strong second-quarter results with revenue up 10.2% and adjusted EPS …

Canandaigua National Bank & Trust Co. Acquires New Stake in AbbVie Inc. $ABBV

Canandaigua National Bank & Trust Co. has acquired a new stake in AbbVie Inc., purchasing 27,540 shares valued at approximately $6.93 million. This comes as AbbVie reported strong second-quarter results, exceeding analyst expectations with revenue up 10.2% year-over-year and solid EPS. The company also …

BrightView Holdings (BV) Misses Q3 Earnings and Revenue Estimates

BrightView Holdings (BV) reported Q3 earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.28, and revenues of $717.6 million, also below estimates. This marks the third time in four quarters the company has missed EPS expectations. Despite underperforming the market year-to-date, …

Why BrightView Holdings Stock Tanked Today

BrightView Holdings (NYSE: BV) stock got smacked with an investor sell-off on Tuesday. The catalyst was the company's fiscal third-quarter results, which, despite a guidance raise for a key line item, missed analyst estimates for both revenue and profitability. Two metrics, two different trajectories …

AbbVie (ABBV) Wins FDA Review For BOTOX Cosmetic In Jawline Treatment Push

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat …

Brightview Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

Brightview Holdings Inc has released its earnings summary for the quarter that ended on June 30. The report details the company's financial performance during this period.

BrightView Reports Third Quarter Fiscal 2026 Results With Second Consecutive Quarter of Land Maintenance Revenue Growth

AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

This article analyzes AbbVie Inc.'s recent earnings beat and the subsequent adjustments made by financial analysts to their future predictions. It will likely cover the company's financial performance, the reasons behind the beat, and how these updated analyst ratings might affect investor sentiment and …

AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition

AbbVie Inc. has initiated a $10 billion bond sale to finance its acquisition of Apogee Therapeutics, as reported by Bloomberg and MT Newswires. This move comes alongside several other recent news items for AbbVie, including positive recommendations for Ubrelvy reimbursement in Canada and FDA …

Pharvaris (PHVS) Projected to Release Quarterly Earnings on Tuesday

ABVC BioPharma, Inc. Files Form 8-K: Key Corporate Details and NASDAQ Listing Information

ABVC BioPharma, Inc. (NASDAQ: ABVC) has postponed the distribution of BioKey (Cayman), Inc. ordinary shares, originally set for August 3, 2026, due to pending administrative, regulatory, and tax matters. While the record date and distribution ratio remain unchanged, the ex-dividend date will be reset …

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share …

AbbVie (ABBV) Lifted Guidance, Has The Market Already Priced It In?

AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal

AbbVie Inc. is reportedly looking to raise at least $8 billion, and potentially up to $10 billion, through an investment-grade bond offering. The pharmaceutical giant intends to use these funds to finance a portion of its acquisition of Apogee Therapeutics Inc. The final size …

Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating

Guggenheim has increased its price target for AbbVie (NYSE: ABBV) to $288 from $261, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst revisions for AbbVie, with Rothschild & Co Redburn also adjusting its target to $285 and Oppenheimer …

ABVC postpones BioKey share distribution; ratio, record date unchanged

ABVC Biopharma has postponed the planned August 3 distribution of BioKey ordinary shares to address administrative, regulatory, and tax matters. The distribution ratio of 0.169464 BioKey shares per ABVC common share and the record date remain unchanged. ABVC will announce new distribution and ex-dividend …

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

If approved, BOTOX®Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle …

UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment

UBRELVY®(ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC)is supported by evidence from the pivotal Phase 3 ACHIEVE I and ACHIEVE II studies. CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults. Migraine affects an estimated 5 million Canadians with the …

BrightView (NYSE:BV) Misses Q2 CY2026 Sales Expectations, Stock Drops

BrightView (BV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Analysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received an average rating of "Moderate Buy" from analysts, with four out of six recommending a buy. The average 12-month price target is $7.33, significantly higher than the recent share price of $1.71. Despite missing revenue estimates, the company …

Enterprise value to revenue forward of BV Financial, Inc. – NASDAQ:BVFL

This article focuses on the enterprise value to revenue forward metric for BV Financial, Inc. (NASDAQ: BVFL). It appears to be a stub or an incomplete financial data point from a larger platform. The content primarily lists market data providers and copyright information, without …

AbbVie’s Growth Now Leans On A Single Molecule

AbbVie's future growth is heavily reliant on a single drug, SKYRIZI, which is projected to account for close to one-third of the company's total revenue in 2026. While the patent for SKYRIZI extends well into the 2030s, the company faces a challenge with its …

Proqr Therapeutics Insider Bought Shares Worth $353,960, According to a Recent SEC Filing

An insider at ProQR Therapeutics N.V. (NASDAQ: PRQR) recently purchased shares valued at $353,960. This transaction was disclosed in a recent SEC filing. ProQR Therapeutics is a biotechnology company focused on developing RNA-based therapeutics for severe genetic disorders.

AbbVie Inc. stock underperforms Monday when compared to competitors

AbbVie Inc. (ABBV) stock fell 2.33% on Monday, closing at $245.10, despite a generally positive trading session where the S&P 500 and Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for AbbVie, underperforming its competitors. The article …

ProQR Therapeutics (PRQR) CEO boosts stake with 200,000-share buy

ProQR Therapeutics N.V. CEO Daniel Anton de Boer recently purchased 200,000 Ordinary Shares at $1.7698 per share, increasing his direct holdings to 500,000 shares. This transaction, categorized as an open market or private purchase, was disclosed in a Form 4 filing and indicates a …

AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says

AbbVie (ABBV) reported another "strong" quarter operationally, with investor attention increasingly PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

AbbVie Inc. 2026: Revenue $16.99B, EPS $2.03— 10-Q Summary

AbbVie Inc. reported its 2026 quarterly results, with revenue reaching $16.99 billion and diluted EPS at $2.03, marking significant growth over the prior year. This performance was attributed to strong sales of key brands like Skyrizi, Rinvoq, and neuroscience products, despite a decline in …

Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight

DelveInsight Business Research LLP The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering …

Canaccord raises Abbvie stock price target to $290 on Q2 beat

Canaccord Genuity increased its price target for Abbvie Inc. (NYSE:ABBV) to $290 from $282, maintaining a Buy rating, following the company's strong second-quarter performance. Abbvie exceeded revenue and earnings expectations, particularly in its Immunology and Neuroscience franchises, leading to a raised 2026 revenue guidance. …

AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter

Morningstar is maintaining its $200 fair value estimate for wide-moat AbbVie following a strong second quarter, which saw 10.2% top-line growth and 22.9% adjusted diluted EPS growth. The company's immunology portfolio, particularly Skyrizi and Rinvoq, continues to drive strong double-digit growth, despite increasing competition. …

ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

AbbVie Inc. ABBV paired strong product momentum with a more complex 2026 outlook. Management raised revenue expectations, while the planned Apogee Therapeutics acquisition pushed adjusted earnings guidance modestly lower. The call focused on Skyrizi, Rinvoq and neuroscience growth, the case for Apogee and a …